Duodenal Jejunal Bypass for Type 2 Diabetes (DJBD)

Phase 1

• Conditions: Diabetes Mellitus

• Registration Number: NCT00487526
• Lead Sponsor: Ferzli, George S., M.D. F.A.C.S.

Brief Summary

Study the effect of Duodenal jejunal bypass on human adults with type 2 diabetes.

Detailed Description

Adults non obese ( BMI less than 34 ) will undergo duodenal jejunal bypass. The Outcome measures: Blood Sugar, Insulin,HbA1c, CCK,Gastrin, GIP1and 2, Ghrelin, Cholesterol, Triglycerides,FFA, C-Peptide.

Study Timeline

• Study Start: 2007-06
• Study First Submitted: 2007-06-11
• Study First Submitted QC: 2007-06-15
• Study First Posted: 2007-06-18
• Status Verified: 2007-07
• Last Update Submitted: 2007-07-10
• Last Update Posted: 2007-07-11

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 50

Inclusion Criteria

• Adults age 20-65
• Clinical diagnosis of type 2 diabetes
• Non obese with BMI less than 34.
• Oral agents or insulin to control T2DM.
• Inadequate control of diabetes as defined as HbA1c>/7.5
• Understanding of the mechanisms of action of the treatment

Exclusion Criteria

• Children with type 1 diabetes
• Obese with BMI over 34
• Coagulopathy
• Liver cirrhosis
• Unable to comply with study requirements, follow-up or give valid consent
• Currently pregnant
• Previous upper abdominal surgery
• Inabilty to tolerate general anesthesia

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Primary Outcome Measures

Name	Time	Method
control of type 2 diabetes in non obese adults	two years

Secondary Outcome Measures

Name	Time	Method
CCK FFA,Cholesterol,Ghrelin,C-peptide,HbA1c,Gastrin,GIP,Triglycerides,Insulin	2 years

Trial Locations

Locations (1)

Center for Advance Medicine Abel Gonzalez; 🇩🇴 Santo Domingo, Dominican Republic